Turn Therapeutics Inc.
TTRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TTRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TTRX
Turn Therapeutics Inc. (TTRX) is a clinical-stage biopharmaceutical company developing drug candidates for dermatological and infectious diseases, with a dual-path strategy that also includes medical device partnerships to generate near-term revenue.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Turn Therapeutics Inc..
Turn Therapeutics Inc. (TTRX) is a clinical-stage biopharmaceutical company developing drug candidates for dermatological and infectious diseases, with a dual-path strategy that also includes medical device partnerships to generate near-term revenue.
- As of June 30, 2026, the company had cash and equivalents of $10.3 million, shareholders' equity of $1.8 million, and total debt of $7.3 million [sec].
- The company has an accumulated deficit of approximately $29.2 million as of June 30, 2026, and expects operating losses to increase due to later-stage clinical trials [sec_mda · as of 2026-08-12].
- Turn Therapeutics is pursuing Phase 3 trials for atopic dermatitis (AD) and onychomycosis, and a Phase 2a study in hidradenitis suppurativa (HS) [sec_mda · as of 2026-08-12].
- The company's growth strategy is built around a dual-path model: pharmaceutical drug development for long-term value and medical device partnerships for near-term revenue [sec · filed 2025-10-09].
- Turn Therapeutics has three FDA clearances for medical devices, two of which were obtained by the fourth quarter of 2017 [sec · filed 2025-09-02].
What works
- The company has a dual-path model that combines pharmaceutical drug development with medical device partnerships, potentially providing near-term revenue while pursuing longer-term drug approvals [sec · filed 2025-10-09].
- Turn Therapeutics has three FDA clearances for medical devices, indicating some regulatory experience and commercial infrastructure [sec · filed 2025-09-02].
- The company is targeting markets with patent expirations and stagnant innovation, which could create opportunities for differentiated therapies [sec · filed 2025-09-02].
What to weigh
- The company has substantial doubt about its ability to continue as a going concern, with cash of $10.3 million as of June 30, 2026, and estimated funding needs of $60–$65 million for Phase 3 trials [sec_mda · as of 2026-08-12].
- Turn Therapeutics has an accumulated deficit of $29.2 million as of June 30, 2026, and expects operating losses to increase substantially for the foreseeable future [sec_mda · as of 2026-08-12].
- The company will need substantial additional funding to support operations and may be unable to raise capital on favorable terms or at all [sec_mda · as of 2026-05-11].
- The company's business is dependent on successful clinical trials and FDA clearances/approvals, which are inherently risky and uncertain [sec · filed 2025-09-02].
From the filings
Quoted directly from source documents.
The company has substantial doubt about its ability to continue as a going concern.
“12 months from the date that the accompanying unaudited condensed consolidated interim financial statements as of June 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.”
SEC MD&A · August 12, 2026
The company requires $60–$65 million to complete Phase 3 trials for AD and onychomycosis.
“We currently anticipate that we will require up to approximately $60 to $65 million to complete our planned Phase 3 trials for AD and onychomycosis, and approximately $2.5 million for our Phase 2a study in HS”
SEC MD&A · August 12, 2026
The company has an accumulated deficit of $29.2 million as of June 30, 2026.
“30, 2026, we had an accumulated deficit of approximately $29.2 million.”
SEC MD&A · August 12, 2026
The company's growth strategy is a dual-path model combining drug development and medical device partnerships.
“Our growth strategy is built around a dual-path model that focuses on the longer-term value creation of pharmaceutical drug development as supplemented by the near-term revenue potential of medical device partnerships.”
SEC filings · October 9, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company has substantial doubt about its ability to continue as a going concern due to limited cash and high funding needs [sec_mda · as of 2026-08-12].
- Significant funding requirement — The company needs $60–$65 million for Phase 3 trials and may not be able to raise capital on favorable terms [sec_mda · as of 2026-08-12].
- Accumulated deficit and losses — The company has an accumulated deficit of $29.2 million and expects operating losses to increase [sec_mda · as of 2026-08-12].
- Dependence on clinical and regulatory success — The company's business depends on successful clinical trials and FDA approvals, which are inherently risky [sec · filed 2025-09-02].
What to watch
- Progress and results of Phase 3 trials for atopic dermatitis and onychomycosis [sec_mda · as of 2026-08-12].
- Ability to raise additional capital through equity or debt financing [sec_mda · as of 2026-05-11].
- Outcomes of the Phase 2a study in hidradenitis suppurativa [sec_mda · as of 2026-08-12].
- Any new medical device partnerships or licensing agreements [sec · filed 2025-10-09].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Turn Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Turn Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
33.6 months
D/E 23.69 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
- % of float
- -
- Days to cover
- —
- Shares short
- -
- Daily short volume (May 7, 2026)
- 54.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TTRX short interestFrequently asked questions
What is the AI investment thesis for Turn Therapeutics Inc.?
Turn Therapeutics Inc. (TTRX) is a clinical-stage biopharmaceutical company developing drug candidates for dermatological and infectious diseases, with a dual-path strategy that also includes medical device partnerships to generate near-term revenue.
What is Turn Therapeutics Inc.'s lead drug candidate?
Turn Therapeutics Inc.'s most advanced tracked candidate is gx-03 (Phase 2) for onychomycosis.
Who is the CEO of Turn Therapeutics Inc.?
Mr. Bradley E. Burnam is the chief executive officer of Turn Therapeutics Inc. (TTRX).
Where is Turn Therapeutics Inc. headquartered?
Turn Therapeutics Inc. (TTRX) is headquartered in Westlake Village, CA, United States.
What therapeutic areas does Turn Therapeutics Inc. focus on?
Turn Therapeutics Inc. develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.